Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3102710 45 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes. © 2021 Elsevier Ltd
Έτος δημοσίευσης:
2021
Συγγραφείς:
Moreau, P.
Kumar, S.K.
San Miguel, J.
Davies, F.
Zamagni, E.
Bahlis, N.
Ludwig, H.
Mikhael, J.
Terpos, E.
Schjesvold, F.
Martin, T.
Yong, K.
Durie, B.G.M.
Facon, T.
Jurczyszyn, A.
Sidana, S.
Raje, N.
van de Donk, N.
Lonial, S.
Cavo, M.
Kristinsson, S.Y.
Lentzsch, S.
Hajek, R.
Anderson, K.C.
João, C.
Einsele, H.
Sonneveld, P.
Engelhardt, M.
Fonseca, R.
Vangsted, A.
Weisel, K.
Baz, R.
Hungria, V.
Berdeja, J.G.
Leal da Costa, F.
Maiolino, A.
Waage, A.
Vesole, D.H.
Ocio, E.M.
Quach, H.
Driessen, C.
Bladé, J.
Leleu, X.
Riva, E.
Bergsagel, P.L.
Hou, J.
Chng, W.J.
Mellqvist, U.-H.
Dytfeld, D.
Harousseau, J.-L.
Goldschmidt, H.
Laubach, J.
Munshi, N.C.
Gay, F.
Beksac, M.
Costa, L.J.
Kaiser, M.
Hari, P.
Boccadoro, M.
Usmani, S.Z.
Zweegman, S.
Holstein, S.
Sezer, O.
Harrison, S.
Nahi, H.
Cook, G.
Mateos, M.-V.
Rajkumar, S.V.
Dimopoulos, M.A.
Richardson, P.G.
Περιοδικό:
The lancet oncology
Εκδότης:
The Lancet Publishing Group
Τόμος:
22
Αριθμός / τεύχος:
3
Σελίδες:
e105-e118
Λέξεις-κλειδιά:
bortezomib; carfilzomib; daratumumab; dexamethasone; doxorubicin; elotuzumab; idecabtagene vicleucel; isatuximab; lenalidomide; melphalan; panobinostat; pomalidomide; prednisone; antineoplastic agent, cancer recurrence; cancer survival; clinical practice; drug efficacy; drug safety; fatigue; gastrointestinal disease; health care policy; high income country; human; intention to treat analysis; low income country; middle income country; minimal residual disease; multiple myeloma; overall survival; practice guideline; progression free survival; refractory multiple myeloma; Review; systematic review; thrombocytopenia; drug effect; drug resistance; multiple myeloma; pathology; salvage therapy; tumor recurrence, Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Salvage Therapy
Επίσημο URL (Εκδότης):
DOI:
10.1016/S1470-2045(20)30756-7
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.